State Bills Setting Specialty Tier Limits Await Health Reform Developments
Legislation is pending in a number of states that would ban or set limits around the use of formulary specialty tiers in private insurance. However, most of the bills appear to be on hold pending implementation over the next six to eight months of new insurance requirements under the health reform law.
You may also be interested in...
HHS proposes to use USP’s drug classification system, created as a guideline for Medicare Part D formularies, to facilitate “review, analysis and comparison” of the breadth of drug coverage offered by individual and small group private insurance plans beginning in 2014.
Biopharmaceutical companies, patient groups and other stakeholders are pushing for federal guidelines specifically barring the use of formulary specialty tiers in private health insurance plans for individuals and small groups.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.